公开(公告)号：US20150366944A1

公开(公告)日：2015-12-24

申请号：US14766151

申请日：2014-02-19

Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.

Inventor： Varda ROTTER ,  Naomi GOLDFINGER ,  Shalom MADAR ,  Yan STEIN

IPC: A61K38/21 ,  C12Q1/68 ,  G01N33/574 ,  C07K14/565 ,  C07K14/56

CPC classification number: A61K38/215 ,  A61K38/212 ,  C07K14/56 ,  C07K14/565 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/156 ,  C12Q2600/158 ,  G01N33/57496 ,  G01N2333/4748

Abstract: The present invention is directed to cancer therapy, specifically to prognostic and therapeutic compositions and methods, wherein expression of a mutated form of p53 serves as a predictive marker for successful type I interferon (IFN) treatment. The invention also relates to the use of low doses of IFN having reduced clinical toxicity, and enables the use of IFN to prevent tumor formation in susceptible patient populations such as patients carrying p53 germline mutations.

Abstract translation: 本发明涉及癌症治疗，特别涉及预后和治疗组合物和方法，其中突变形式的p53的表达用作成功的I型干扰素（IFN）治疗的预测标记。 本发明还涉及使用具有降低的临床毒性的低剂量IFN，并且能够使用IFN来预防易感患者群体如携带p53种系突变的患者的肿瘤形成。